

# Molecular characterization of Glucose-6-Phosphate Dehydrogenase: do single nucleotide polymorphisms affect hematological parameters in HIV positive patients?

**CURRENT STATUS:** POSTED



Kwabena Owusu Danquah  
Kwame Nkrumah University of Science and Technology

Kofi Mensah  
Kwame Nkrumah University of Science and Technology

Charles Nkansah  
Kwame Nkrumah University of Science and Technology

Samuel Kwasi Appiah  
Kwame Nkrumah University of Science and Technology

Mark Noagbe  
Kwame Nkrumah University of Science and Technology

Yasmine Hardy  
Komfo Anokye Teaching Hospital

David O. Ntiamoah  
Kwame Nkrumah University of Science and Technology

Lillian Antwi Boateng  
Kwame Nkrumah University of Science and Technology

Max Efui Annani-Akollor  
Kwame Nkrumah University of Science and Technology

Eddie-Williams Owiredu  
Kwame Nkrumah University of Science and Technology

Alexander Yaw Debrah  
Kwame Nkrumah University of Science and Technology College of Health Sciences

Otchere Addai-Mensah  
Kwame Nkrumah University of Science and Technology

✉ drmedmozart@yahoo.com *Corresponding Author*

**DOI:**

10.21203/rs.2.22175/v1

**SUBJECT AREAS**

*Hematology*

**KEYWORDS**

*Human Immuno-Deficiency, Glucose-6-Phosphate Dehydrogenase, Single Nucleotide Polymorphisms, Hematological parameters*

## Abstract

**Objectives:** This descriptive, cross-sectional study aimed at evaluating the prevalence of G6PD deficiency, the 376A → G, 202G → A single nucleotide polymorphisms (SNPs) among HIV patients attending care at a teaching hospital in Ghana and determine if the SNPs are associated with a deranged hematological profile.

**Results:** Out of the 200 participants, 13.0% (26/200) were G6PD deficient based on the methemoglobin reductase technique, with 1.5% (3/200) and 11.5% (23/200) presenting with partial and full enzyme defect, respectively. Among the 13.0% participants with G6PD deficiency, 19.2% (5/26), 30.8% (8/26), and 19.2% (5/26) presented with 376A → G only [Enzyme activity (EA): 1.19 U/g Hb], 202G → A only [EA: 1.41 U/g Hb], and G202/A376 SNPs [EA: 1.14 U/g Hb], respectively. Having the 376A → G mutation was associated with lower red blood cell (RBC) count [3.38 x10<sup>6</sup>/μL (3.16-3.46) vs 3.95 x10<sup>6</sup>/μL (3.53-4.41), p=0.010], but higher mean cell volume (MCV) [102.90 (99.40-113.0) vs 91.10 fL (84.65-98.98), p=0.041] and mean cell hemoglobin (MCH) [33.70 pg (32.70-38.50) vs 30.75 pg (28.50-33.35), p=0.038] whereas possessing the 202G → A mutation was associated with higher MCV only [98.90 fL (90.95-102.35) vs 91.10 fL (84.65-98.98), p=0.041] compared to G6PD non-deficient participants.

## Introduction

Human Immunodeficiency virus (HIV) is a chronic viral infection and a serious public health concern. Currently, approximately 37.9 million people are living with HIV worldwide [1]. In Ghana, 330 000 people are living with HIV [2].

HIV infection is associated with persistent inflammation and immune activation leading to production of reactive oxygen molecules and oxidative stress [3, 4]. Additionally, HIV positive individuals are predisposed to a plethora of other infections which may result in oxidative stress. The sequelae of these oxidative stress are particularly alarming and life-threatening in people comorbid with Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency. The prevalence rate of G6PD deficiency is 5–25% in tropical Africa and Asia [5–7]. In Ghana, the prevalence of G6PD deficiency is 15–26% [8, 9].

Over 400 G6PD variants have been identified [10] and the polymorphisms are predominantly defined

to specific geographic locations [11]. About 186 of these variants are associated with G6PD deficiency due to decreasing enzyme activity or stability [5, 12, 13]. In sub-Saharan Africa, the predominant G6PD variants are B, A, and A-, with frequencies greater than 1% [14]. The G6PD B variant possesses the 376A cDNA sequence and has been shown to have normal enzyme activity. Likewise, the G6PD A variant, which carries a cDNA mutation A376G, has about 85% of the normal enzyme activity. On the contrary, the G6PD A- variants carry the G6PD A backbone with an added single nucleotide mutation. The most common G6PD A- variant possesses the A376G/G202A mutation and has been reported to have 10% of normal enzyme activity in their red blood cells (RBC), although their white blood cells (WBC) maintain 100% normal enzyme activity [15]. Other A- variants peculiar to sub-Saharan Africa are the A376G/T968C, A376G/G680T, and A376G/A543T [16].

In some conditions such as malaria, before primaquine administration, G6PD deficiency is screened for. However, the advantage of screening HIV positive patients for G6PD deficiency is often overlooked despite reports indicating worse clinical outcomes in people comorbid with HIV and G6PD deficiency [17–19]. Importantly, HIV and G6PD deficiency have individually being linked with deranged hematological profile. HIV affects all hematological cell lines, as evidenced by anaemia, neutropaenia, lymphopaenia, and thrombocytopaenia [20–23] whereas G6PD deficiency is associated with attenuated levels of haemoglobin (Hb), haematocrit (HCT), mean cell volume (MCV), and mean cell haemoglobin (MCH) [24]. Notwithstanding, studies on G6PD deficiency in HIV patients is limited in Africa, where both conditions are prevalent and none has been conducted in Ghana.

This study, thus, aimed at evaluating the prevalence of G6PD deficiency, the 376A → G, 202G → A single nucleotide polymorphisms (SNPs) among HIV patients attending care at a teaching hospital in Ghana and determine if the SNPs are associated with deranged hematological profile.

## Methods

### Study Design/Area

This descriptive, cross-sectional study was carried out between June 2018 and May 2019 at the HIV clinic of Komfo Anokye Teaching Hospital (KATH) in Kumasi.

### Study Population

The sample size for the study was calculated using Fischer's sampling formula ( $n = \frac{z^2 pq}{d^2}$ ), where  $z$  is the critical value of the normal distribution (1.96 at 95% CI);  $p$  is the estimated prevalence of G6PD deficiency in Ghana (15%) [8];  $d$  is the absolute precision or sampling error tolerated = 5%. From the above equation, a total of 200 consecutive consenting HIV positive Ghanaians, aged 15 years and above, were recruited during their routine clinic visit days. All participants were on ART. Participants on sulfate and copper containing medications, those who were very ill and pregnant women were exempted from the study. Participants' selection protocol is shown in Additional file 1: Fig. S1.

#### Sample collection and assay

Six milliliters (6 ml) of venous blood was obtained from each participant under aseptic conditions for laboratory assessments. Complete blood count was evaluated using XN 2000 fully automated Sysmex Haematology analyzer (Sysmex Corporation, Kobe, Japan). G6PD screening was performed with the methemoglobin reductase technique as described by Brewer et al. [25] and patients were grouped into "normal", "partial defect" and "full defect" based on the color of the test solution as described by Antwi-Baffour et al. [26] (Details in Additional file 1: Table S1). G6PD enzyme activity assay was done for samples that were G6PD deficient (both "full" and "partial defect") during screening by the methemoglobin reductase technique using the Pointe Scientific G6PD kinetic kit according to manufacturer's instructions (Standardized with an intra-assay % CVs of 2.5%-9.2% and inter-assay %CVs of 2.1%-11.4%) (Pointe Scientific Limited, UK). In preparation for G6PD genotyping, DNA was extracted from the blood samples that were G6PD deficient during screening. Extraction was based on the double salt precipitation method as previously described [27]. A large number of single nucleotide polymorphisms (SNPs) have been identified to be associated with G6PD deficiency in Africa [10, 11, 16]. However, 376A → G, 202G → A SNPs are the most commonly reported in Ghana [14, 28] and were thus selected for this study. For the 376A → G mutation, the forward and reverse primer sequences used were 5'-CCCAGGCCACCCAGAGGAGA-3' and 5'-CGGCCCCGGACACGCTCATAG-3', respectively whereas those for the 202G → A mutation were 5'-CACCACTGCCCTGTGACCT-3' and 5'-GGCCCTGACACCACCCACCTT-3', respectively (Inqaba Biotech Ltd, South Africa). The PCR cycling conditions were; one cycle of initial denaturation at 94 °C for 5 minutes, denaturation at 94 °C for 45

seconds, annealing at 56 °c for 30 seconds and extensions at 74° C for 45 seconds followed by five cycles of final extension at 74° c for 5minutes (For 35 cycles). The amplified products were separated by electrophoresis on 1% agarose gels stained with ethidium bromide and visualized under UV light for the presence of bands indicative of 376A → G and 202G → A mutations (Additional file 1: Fig. S2).

### Statistical Analysis

Statistical analysis and graphical presentation were performed using the R Language for Statistical Computing version 3.5.2 (R Core Team, Vienna, Austria) [29]. Categorical data were presented as frequencies (percentages). Normality of continuous data was evaluated using Shapiro-Wilk's test. All continuous data were non-parametric and were presented as medians (interquartile ranges).

Significance of differences of hematological parameters between various variants of G6PD were tested with Kruskal-Wallis tests, followed by Dunn's post-hoc multiple comparison tests. All statistical tests were two-sided and a  $p$ -value  $< 0.05$  was considered statistically significant.

### Results

A total of 200 participants with an average age of 42.0 (35.0–50.0) years were included in this study. A higher proportion were females (84.0%) and had basic education (65.5%). The average RBC count, Hb, MCV, MCH, platelet (PLT) count, and WBC count were  $3.88 \times 10^6/\mu\text{L}$ , 12.0 g/dL, 91.75 fL, 31.25 pg,  $222.0 \times 10^3/\mu\text{L}$ , and  $5.13 \times 10^3/\mu\text{L}$ , respectively (Table 1).

Table 1  
Baseline characteristics of the study population

Variables	Frequency (n = 200)	Percentage (%)
Demographic		
Sex		
Female	168	84.0
Male	32	16.0
Age (years)*	42.0	35.0–50.0
Educational level		
Illiterate	44	22
Basic	131	65.5
Secondary	19	9.5
Tertiary	6	3.0
Hematological*		
RBC count ( $\times 10^6/\mu\text{L}$ )	3.88	3.47–4.34
Hb (g/dL)	12.00	10.97–13.10
MCV (fL)	91.75	85.05–100.0
MCH (pg)	31.25	28.80–34.33
PLT count ( $\times 10^3/\mu\text{L}$ )	222.0	196.80–591.00
WBC count ( $\times 10^3/\mu\text{L}$ )	5.13	4.83–6.17

\*Data presented as median and interquartile ranges

Out of the 200 participants screened using the methemoglobin reductase technique, 13.0% (26/200) were G6PD deficient, with 1.5% (3/200) and 11.5% presenting with partial and full enzyme defects, respectively (Fig. 2a). Among the 13.0% (23/200) with G6PD deficiency, 19.2% (5/26), 30.8% (8/26), and 19.2% (5/26) presented with 376A → G only, 202G → A only, and G202/A376 SNPs, respectively (Fig. 2b). Upon stratification by sex, 4, 7, 4, and 5 of the females, and 1, 1, 1, and 2 of the males had the 376A → G only and 202G → A only, G202/A376 SNPs, and no band, respectively (Fig. 2c). The likelihood of being phenotypically classified as G6PD full defect was higher among participants having the G202/A376 SNPs compared to the 202G → A SNP (Additional file 1: Table S2).

Participants with only the 376A → G mutation presented with significantly lower RBC count [ $3.38 \times 10^6/\mu\text{L}$  (3.16–3.46) vs  $3.95 \times 10^6/\mu\text{L}$  (3.53–4.41),  $p = 0.010$ ], but higher MCV [102.90 (99.40–113.0) vs 91.10 fL (84.65–98.98),  $p = 0.041$ ] and MCH [33.70 pg (32.70–38.50) vs 30.75 pg (28.50–33.35),  $p = 0.038$ ] compared to G6PD non-deficient participants. On the other hand, participants with only the 202G → A mutation had significantly higher MCV [98.90 fL (90.95–102.35) vs 91.10 fL (84.65–98.98),  $p = 0.041$ ]. No statistically significant association was found between haemoglobin level, PLT, and WBC counts and G6PD variants (Fig. 3).

## Discussion

This study reports a 13.0% prevalence of G6PD deficiency, comprising 5% and 11.5% partial and full enzyme defect, respectively, based on methemoglobin reductase technique. Our finding is consistent with a retrospective study by Tungsiripat et al. among HIV patients in the United States. After screening 212 Blacks infected with HIV, they found 28 (13.2%) to be G6PD deficient [30]. In another study by Serpa et al. [31] in the United States, 6.8% of all HIV-infected adults had G6PD deficiency which is lower compared to this present study. The disparity in the prevalence rates could be linked to the fact that Serpa et al. included participants of diverse race (African Americans, Hispanics, Whites and Asian-Pacific). Evidence suggests that the prevalence of G6PD deficiency is very low among whites compared to blacks [30, 32]. Thus, the inclusion of Caucasians may have attenuated the prevalence rate found in their study. Our finding also falls within the prevalence range of 5–25% found in tropical Africa, the Middle East, tropical and sub-tropical Asia, some parts of the

Mediterranean, and in Papua New Guinea [5–7].

In this study, among the participants with G6PD deficiency, we found 19.2% to harbor the G6PD A- allele (G202/A376) which is associated with reduced enzyme activity [15]. A study by Xu et al. in the Dominican Republic also reported a similarly high prevalence of the G6PD A- variant among HIV-infected patients [33]. Of note, we also observed that, among those with G6PD deficiency based on the methemoglobin reductase technique, 30.8% presented with no band on electrophoresis. It is possible that these patients harbored other G6PD variants such as the A376G/T968C, A376G/G680T, and A376G/A543T which are also peculiar to sub-Saharan Africa [16]. Importantly, seven and four of the females versus one and two of the males had the G6PD A and G6PD A- allele, respectively. Congruently, more females than males with the G6PD A- variants have been reported in previous studies in Ghana [14, 28]. An explanation could be the higher number of females in this study compared to males. The consistently higher number of HIV positive females compared to males in Kumasi justifies the gender disparity [34, 35].

Another finding of this study is that the presence of only the 376A → G mutation was associated with lower RBC count, but higher MCV and MCH whereas possessing only the 202G → A mutation was only associated with significantly higher MCV. The relatively greater deranged hematological profile in the participants with the 376A → G compared to the 202G → A could be attributed to the comparatively lower G6PD enzyme activity among participants with the 376A → G mutation compared to the 202G → A mutation, although not statistically significant (Additional file 1: Fig. S3). In a study to find the association between G6PD deficiency and hematological parameters in children from Botswana, Motshoge et al. made similar observations [36]. The increased MCV due to the 202G → A mutation is also in harmony with a GWAS study by Ding et al. [37]. Other reports such as those by Ajlaan [38] and Domingos et al. [39] are in line with our study findings.

## Conclusion

This study reports a 13.0% prevalence of G6PD deficiency, comprising 1.5% and 11.5% partial and full enzyme defect, respectively, based on the methemoglobin reductase technique among HIV patients in Ghana. Among G6PD deficient HIV patients, the prevalence of G202/A376 SNPs is 19.2%. The 376A

→ G mutation is associated with lower RBC count, but higher MCV and MCH whereas the 202G → A mutation is associated with higher MCV.

## Limitations

Unavailability of data on important modifying genotypes such as HbS; alpha-thalassemia 3.7 deletion as well as data on ART; its adherence and CD4 count is a limitation of this study. This study is also limited by the relatively small sample size and the cross-sectional design used which precluded comparison with non-HIV group. Larger sample sizes in future studies will be ideal.

## Abbreviations

HIV

Human Immunodeficiency virus

G6PD

Glucose-6-phosphate dehydrogenase

SNP

Single nucleotide polymorphisms

Hb

Hemoglobin

HCT

Hematocrit

RBC

Red blood cell

WBC

White blood cell

PLT

Platelet

MCV

Mean cell volume

MCH

Mean cell hemoglobin

## Declarations

### **Ethics approval and consent to participate**

This study was approved by the Committee on Human Research Publication and Ethics (CHRPE) of the School of Medical Sciences, Kwame Nkrumah University of Science and Technology. Written informed

consent was obtained from all participants who opted to participate after the aims and objectives of the study was explained to them.

### **Consent for publication**

Not applicable.

### **Availability of data and material**

The datasets supporting the conclusions of this article are included within the article and its supporting file.

### **Competing interests**

The authors declare that they have no competing interests.

### **Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### **Authors' contributions**

OAM, AYD and KOD designed the study, supervised the research and laboratory analysis and revised the manuscript. KM, CN, SKA, MN, YH, DON, LAB and MEAA were involved in the collection of data, laboratory analysis and revision of the manuscript. EWO was involved in the statistical analysis and interpretation, drafting and revision of the manuscript. All authors read and approved the final manuscript.

### **Acknowledgements**

The authors are grateful to the Staff of the Komfo Anokye Teaching Hospital; the School of Medicine and Dentistry, KNUST and all who actively participated in the study.

### **Additional File**

Additional file 1. Flowchart of the protocol for the selection of study subjects; Gel image of SNPs used in this study; Comparison of G6PD enzyme activity by the presence of 376A → G only and 202G → A only and G202/A376 SNPs.

### **References**

1. UNAIDS. Global HIV & AIDS statistics — 2019 fact sheet: Joint United Nations

Programme on HIV/AIDS; 2019 [25/11/2019]. Available from:

<https://www.unaids.org/en/resources/fact-sheet>.

2. UNAIDS. AIDSinfo 2018: Joint United Nations Programme on HIV/AIDS; 2018 [cited 27/11/2019]. Available from: <http://aidsinfo.unaids.org/>.
3. Ipp H, Zemlin A. The paradox of the immune response in HIV infection: when inflammation becomes harmful. *Clinica chimica acta*. 2013;416:96-9.
4. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. *The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland*. 2008;214(2):231-41.
5. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. *The lancet*. 2008;371(9606):64-74.
6. Drousiotou A, Touma EH, Andreou N, Loiselet J, Angastiniotis M, Verrelli BC, et al. Molecular characterization of G6PD deficiency in Cyprus. *Blood Cells, Molecules, and Diseases*. 2004;33(1):25-30.
7. Karimi M, Yavarian M, Afrasiabi A, Dehbozorgian J, Rachmilewitz E. Prevalence of  $\beta$ -thalassemia trait and glucose-6-phosphate dehydrogenase deficiency in Iranian Jews. *Archives of medical research*. 2008;39(2):212-4.
8. Adu P, Simpong DL, Takyi G, Ephraim RK. Glucose-6-phosphate dehydrogenase deficiency and sickle cell trait among prospective blood donors: a cross-sectional study in Berekum, Ghana. *Advances in hematology*. 2016;2016.
9. WHO. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. *Bull World Health Organ*. 1989;67(6):601-11. PubMed PMID: 2633878.
10. Beutler E. G6PD: population genetics and clinical manifestations. *Blood reviews*. 1996;10(1):45-52.
11. Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. *Best*

Practice & Research Clinical Haematology. 2000;13(1):21-38.

12. Beutler E, Vulliamy TJ. Hematologically important mutations: glucose-6-phosphate dehydrogenase. *Blood cells, molecules, and diseases*. 2002;28(2):93-103.
13. Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations. *Blood Cells, Molecules, and Diseases*. 2012;48(3):154-65.
14. Amoah LE, Opong A, Ayanful-Torgby R, Abankwa J, Acquah FK. Prevalence of G6PD deficiency and Plasmodium falciparum parasites in asymptomatic school children living in southern Ghana. *Malaria journal*. 2016;15(1):388.
15. Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. *Blood reviews*. 2007;21(5):267-83.
16. Enevold A, Vestergaard LS, Lusingu J, Drakeley CJ, Lemnge MM, Theander TG, et al. Rapid screening for glucose-6-phosphate dehydrogenase deficiency and haemoglobin polymorphisms in Africa by a simple high-throughput SSOP-ELISA method. *Malaria journal*. 2005;4(1):61.
17. Aukrust P, Muüller F, Svardal AM, Ueland T, Berge RK, Frøland SS. Disturbed glutathione metabolism and decreased antioxidant levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy —potential immunomodulatory effects of antioxidants. *The Journal of infectious diseases*. 2003;188(2):232-8.
18. Feily A, Namazi MR. Glucose-6-phosphate-dehydrogenase deficiency may impart susceptibility to the development of AIDS. *Archives of medical research*. 2011;42(1):77.
19. Staal FJ, Ela SW. Glutathione deficiency and human immunodeficiency virus infection.


- The Lancet. 1992;339(8798):909-12.
20. Saha D, Kini JR, Subramaniam R. A study of the hematological profile of human immunodeficiency virus positive patients in coastal South Indian region. *Journal of Medical Sciences*. 2015;35(5):190.
  21. Ofosu DN, Debrekyei YM, Duah J, Donkor L, Owiredu E-W. Haematological Profile of Hiv Patients In Relation to Immune Status in Kumasi, A Case Study. *International Journal of Medical Science and Clinical invention*. 2019;6:4554-8. doi: 10.18535/ijmsci/v6i8.06.
  22. Kirchhoff F, Silvestri G. Is Nef the elusive cause of HIV-associated hematopoietic dysfunction? *The Journal of clinical investigation*. 2008;118(5):1622-5.
  23. Cosby CD. Hematologic disorders associated with human immunodeficiency virus and AIDS. *Journal of infusion Nursing*. 2007;30(1):22-32.
  24. Pengon J, Svasti S, Kamchonwongpaisan S, Vattanaviboon P. Hematological parameters and red blood cell morphological abnormality of Glucose-6-Phosphate dehydrogenase deficiency co-inherited with thalassemia. *Hematology/oncology and stem cell therapy*. 2018;11(1):18-24.
  25. Brewer G, Alvin R, Alf S. The methemoglobin reduction test for erythrocytes: a simplified procedure for detecting a specific hypersusceptibility to drug hemolysis. *Jama*. 1962;180(5):386-88.
  26. Antwi-Baffour S, Adjei JK, Forson PO, Akakpo S, Kyeremeh R, Seidu MA. Comorbidity of Glucose-6-Phosphate Dehydrogenase Deficiency and Sickle Cell Disease Exert Significant Effect on RBC Indices. *Anemia*. 2019;2019.
  27. Sakyi SA, Kumi B, Ephraim RD, Danquah KO, Osakunor D, Baidoe-Ansah D. Modified DNA Extraction Technique for Use in Resource-Limited Settings: Comparison of Salting Out Methods versus QIAamp Blood Mini Kit. *Annals of Medical and Health*

Sciences Research. 2017;7(3).

28. Carter N, Pamba A, Duparc S, Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. *Malaria journal*. 2011;10(1):241.
29. Team RC. R: A language and environment for statistical computing. 2013.
30. Tungsiripat M, Drechsler H, Sarlone C, Amyot K, Laffey E, Aberg J. Prevalence and significance of G6PD deficiency in patients of an urban HIV clinic. *Journal of the International Association of Physicians in AIDS Care*. 2008;7(2):88-90.
31. Serpa JA, Villarreal-Williams E, Giordano TP. Prevalence of G6PD deficiency in a large cohort of HIV-infected patients. *Journal of Infection*. 2010;61(5):399-402.
32. Burka ER, Weaver Z, Marks PA. Clinical spectrum of hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency. *Annals of Internal Medicine*. 1966;64(4):817-25.
33. Xu JZ, Francis RO, Nadal LEL, Shirazi M, Jobanputra V, Hod EA, et al. G6PD deficiency in an HIV clinic setting in the Dominican Republic. *The American journal of tropical medicine and hygiene*. 2015;93(4):722-9.
34. Boateng R, Mutocheluh M, Dompok A, Obiri-Yeboah D, Anto EO, Owusu M, et al. Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naïve individuals in Kumasi, Ghana. *PloS one*. 2019;14(4):e0215377.
35. Frempong MT, Ntiamoah P, Annani-Akollor ME, Owiredu WK, Addai-Mensah O, Owiredu E-W, et al. Hepatitis B and C infections in HIV-1 and non-HIV infected pregnant women in the Brong-Ahafo Region, Ghana. *PloS one*. 2019;14(7).
36. Motshoge T, Ababio G, Aleksenko L, Souda S, Muthoga CW, Mutukwa N, et al. Prevalence of G6PD deficiency and associated haematological parameters in children from Botswana. *Infection, Genetics and Evolution*. 2018;63:73-8.

37. Ding K, De Andrade M, Manolio TA, Crawford DC, Rasmussen-Torvik LJ, Ritchie MD, et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. *G3: Genes, Genomes, Genetics*. 2013;3(7):1061-8.
38. Ajlaan S, Al-Naama L, Al-Naama M. Correlation between normal glucose-6-phosphate dehydrogenase level and haematological parameters. *East Mediterr Health J*. 2000;6:391-5.
39. Domingos I, Hatzlhofer B, Oliveira F, Araujo F, Araujo A, Lucena-Araujo A, et al. Prevalence and molecular defect characterization of glucose-6-phosphate dehydrogenase deficiency in Brazilian blood donors. *International journal of laboratory hematology*. 2015;37(5):e109-e11.

Figures






Figure 1

Prevalence of G6PD deficiency. (a) Phenotypic prevalence of G6PD deficiency based on methemoglobin reductase technique (b) Genotypic prevalence of 376A → G, 202G → A, G202/A376 G6PD variants (c) Genotypic prevalence of 376A → G, 202G → A, G202/A376 G6PD variants by sex.




Figure 2

Comparison of hematological parameters by G6PD genotype.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

Additional file 1.docx